December 25, 2014 6:36 AM ET

Pharmaceuticals

Company Overview of Tolerx, Inc.

Company Overview

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company’s products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc. was formerly known as TolerRx, Inc. and changed its name to Tolerx, Inc. in December 2011. Tolerx, Inc. was founded in 2000 and is based in Cambridge, Massachusetts.

300 Technology Square

3rd Floor

Cambridge, MA 02139

United States

Founded in 2000

Phone:

617-452-1300

Fax:

617-354-8300

Key Executives for Tolerx, Inc.

Co-Founder
Age: 57
Co-Founder
Age: 69
Consultant
Consultant
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
MCR American Pharmaceuticals, Inc. United States
G2B Pharma, Inc. United States
Revive Pharmaceuticals Inc. United States
Sequoia Pharmaceuticals, Inc. United States
G. D. Searle, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tolerx, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.